Pembrolizumab with axitinib for untreated advanced renal cell carcinoma – guidance (TA650)

NICE do not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma in adults. Short-term trial evidence found pembrolizumab with axitinib is more effective than sunitinib, but long-term benefits and cost-effectiveness estimates are uncertain.

National Institute for Health and Care Excellence